Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally.
Moderate growth potential and slightly overvalued.
Share Price & News
How has Endo International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ENDP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ENDP underperformed the US Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: ENDP underperformed the US Market which returned 17.9% over the past year.
Price Volatility Vs. Market
How volatile is Endo International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat You Must Know About Endo International plc's (NASDAQ:ENDP) Beta Value
1 month ago | Simply Wall StImagine Owning Endo International (NASDAQ:ENDP) And Trying To Stomach The 93% Share Price Drop
2 months ago | Simply Wall StIs Endo International plc's (NASDAQ:ENDP) CEO Pay Fair?
Is Endo International undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ENDP ($6.07) is trading below our estimate of fair value ($28.46)
Significantly Below Fair Value: ENDP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ENDP is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: ENDP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ENDP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ENDP has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.
How is Endo International forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENDP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ENDP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ENDP's is expected to become profitable in the next 3 years.
Revenue vs Market: ENDP's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: ENDP's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ENDP's Return on Equity is forecast to be high in 3 years time
How has Endo International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ENDP is currently unprofitable.
Growing Profit Margin: ENDP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ENDP is unprofitable, and losses have increased over the past 5 years at a rate of -16.9% per year.
Accelerating Growth: Unable to compare ENDP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENDP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: ENDP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is Endo International's financial position?
Financial Position Analysis
Short Term Liabilities: ENDP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ENDP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ENDP has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ENDP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: ENDP has a low level of unsold assets or inventory.
Debt Coverage by Assets: ENDP has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ENDP has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ENDP is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -1.5% per year.
What is Endo International's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ENDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ENDP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ENDP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENDP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ENDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Campanelli (57yo)
Mr. Paul V. Campanelli has been the Chief Executive Officer, President, and Executive Director at Endo International plc since September 23, 2016 and has been its Chairman since November 4, 2019. Mr. Campa ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD19.97M) is above average for companies of similar size in the US market ($USD3.81M).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
|Executive VP & CFO||3.2yrs||US$2.64m||0.049% $668.4k|
|Executive VP & COO||3.3yrs||US$3.13m||0.11% $1.5m|
|Executive VP & Chief Legal Officer||4.8yrs||US$2.55m||0.047% $648.5k|
|Senior VP||0.4yrs||no data||0.0072% $98.6k|
|Senior Vice President of Investor Relations & Corporate Affairs||1.5yrs||no data||no data|
|Senior VP & Chief Compliance Officer||1.8yrs||no data||no data|
|Senior VP of Corporate Development & Treasurer||3.2yrs||no data||no data|
|Chief Human Resources Officer||1.1yrs||no data||no data|
|Executive Vice President of Global Quality and Compliance||3.3yrs||no data||no data|
Experienced Management: ENDP's management team is considered experienced (3.2 years average tenure).
|Independent Director||0yrs||no data||no data|
|Independent Director||6yrs||US$315.00k||0.14% $1.9m|
|Senior Independent Director||0.3yrs||US$450.00k||0.090% $1.2m|
|Independent Director||6yrs||US$320.00k||0.041% $563.7k|
|Independent Director||5.6yrs||US$325.00k||0.036% $498.2k|
|Independent Director||6yrs||US$320.00k||0.034% $473.1k|
Experienced Board: ENDP's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Endo International plc's company bio, employee growth, exchange listings and data sources
- Name: Endo International plc
- Ticker: ENDP
- Exchange: NasdaqGS
- Founded: 1920
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.377b
- Shares outstanding: 226.78m
- Website: https://www.endo.com
Number of Employees
- Endo International plc
- Minerva House
- First Floor
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ENDP||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2000|
|EO7||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2000|
|ENDP N||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 2000|
|0Y5F||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 2000|
Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded - Specialty & Established Pharmaceuticals segment provides branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain, and orthopedics. This segment offers XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL Nasal Spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN Gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; FORTESTA Gel for men suffering from hypogonadism; EDEX to treat erectile dysfunction; and TESTIM for TRT in conditions associated with a deficiency or absence of endogenous testosterone. The company’s U.S. Branded - Sterile Injectables segment offers branded sterile injectable products, such as VASOSTRICT, ADRENALIN, and APLISOL; and generic sterile injectable products. Its U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and cardiovascular disease markets. The company’s International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women’s health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. The company was founded in 1920 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 00:34|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.